System and method for treatment of eustachian tube from oral approach
10085889 ยท 2018-10-02
Assignee
Inventors
- Randy S. Chan (San Jose, CA, US)
- Ketan P. Muni (San Jose, CA, US)
- Hung V. Ha (San Jose, CA, US)
- Andy Nguyen (San Jose, CA, US)
Cpc classification
A61B17/22
HUMAN NECESSITIES
A61F11/202
HUMAN NECESSITIES
A61M25/0041
HUMAN NECESSITIES
A61M31/00
HUMAN NECESSITIES
A61B17/24
HUMAN NECESSITIES
International classification
A61F11/00
HUMAN NECESSITIES
A61M5/00
HUMAN NECESSITIES
A61M31/00
HUMAN NECESSITIES
A61B17/24
HUMAN NECESSITIES
Abstract
A method of dilating a first Eustachian tube (ET) and a second ET of a patient using a dilation catheter includes directing the dilation catheter into the mouth of the patient and advancing the dilation catheter into a first ET on one side of the patient's head while a proximal portion of the dilation catheter is disposed in the mouth of the patient. The method further includes expanding the expandable member to thereby dilate the first ET. The method may further include repositioning the dilation catheter relative to a second ET on another side of the patient's head and advancing the dilation catheter into the second ET while a proximal portion of the dilation catheter is disposed in the mouth of the patient. The method may further include expanding the expandable member to thereby dilate the second ET.
Claims
1. A method of dilating a first Eustachian tube (ET) of a patient using a dilation catheter, wherein the method comprises: (a) directing the dilation catheter into the mouth of the patient; (b) advancing the dilation catheter into a first ET on one side of the patient's head while a proximal portion of the dilation catheter is disposed in the mouth of the patient; and (c) expanding an expandable member uniformly in a radial direction to thereby dilate the first ET, wherein the circumference of the expandable member is in contact with the circumference of the first ET.
2. The method of claim 1, further comprising: (a) repositioning the dilation catheter relative to a second ET on another side of the patient's head while the proximal portion of the dilation catheter is disposed in the mouth of the patient; (b) advancing the dilation catheter into the second ET while the proximal portion of the dilation catheter is disposed in the mouth of the patient; and (c) expanding the expandable member to thereby dilate the second ET.
3. The method of claim 1, further comprising: (a) directing a guide member into the mouth of the patient; and (b) advancing at least part of a distal portion of the guide member adjacent to an opening of a first ET on one side of the patient's head; wherein the act of advancing the dilation catheter comprises advancing the dilation catheter relative to the guide member, wherein the guide member directs the dilation catheter into the first ET during the act of advancing the dilation catheter relative to the guide member; wherein a proximal portion of the guide member is disposed in the mouth of the patient during the act of advancing the dilation catheter relative to the guide member.
4. The method of claim 3, wherein the distal portion of the guide member comprises a bend.
5. The method of claim 4, wherein the bend has a bend angle between about 45 and about 65.
6. The method of claim 3, wherein the guide catheter has a length between about 14 cm and about 17 cm.
7. The method of claim 3, further comprising: (a) repositioning the guide catheter relative to a second ET on another side of the patient's head while a proximal portion of the guide catheter is disposed in the mouth of the patient; and (b) advancing the dilation catheter relative to the repositioned guide catheter to thereby drive the dilation catheter into the second ET while a proximal portion of the dilation catheter is disposed in the mouth of the patient.
8. The method of claim 1, wherein the expandable member comprises an inflatable balloon, wherein the act of expanding the expandable member comprises inflating the balloon.
9. The method of claim 1, wherein the expandable member comprises a mechanically expandable element, wherein the act of expanding the expandable member comprises expanding the expandable element.
10. The method of claim 1, further comprising displacing a portion of a soft palate of the mouth.
11. The method of claim 10, wherein displacing the portion of the soft palate comprises tying down the soft palate.
12. The method of claim 1, further comprising delivering a therapeutic agent to the first ET.
13. A method of dilating Eustachian tubes (ETs) of a patient using a dilation catheter, wherein the method comprises: (a) directing the dilation catheter into an oro-nasal cavity of the patient via the patient's mouth; (b) advancing the dilation catheter into a first ET of the patient; (c) expanding an expandable member of the dilation catheter to thereby dilate the first ET; (d) repositioning the dilation catheter toward a second ET of the patient without removing the dilation catheter from the oro-nasal cavity; (e) advancing the dilation catheter into the second ET; and (f) expanding the expandable member of the dilation catheter to there by dilate the second ET.
14. The method of claim 13, wherein the dilation catheter has a length of between about 20 cm and about 40 cm.
15. The method of claim 13, wherein the dilation catheter comprises a shaft, wherein the shaft has a diameter between about 0.7 mm and about 1.1 mm.
16. The method of claim 13, wherein steps (a) through (f) are all performed using a single hand.
17. The method of claim 13, further directing a guide catheter into the oro-nasal cavity of the patient via the patient's mouth, wherein the act of advancing the dilation catheter comprises advancing the dilation catheter through the guide catheter.
18. A method of dilating a Eustachian tube (ET) of a patient using a guide member and a dilation catheter, wherein the method comprises: (a) directing the guide member into a mouth of the patient; (b) directing the dilation catheter into the mouth of the patient via the guide member; (c) advancing at least part of a distal portion of the guide member adjacent to an opening of the ET while a proximal portion of the guide member remains disposed in the mouth of the patient, wherein the distal portion of the guide member has a bend; (d) advancing the dilation catheter relative to the guide member such that an expandable element of the dilation catheter is positioned distal to a distal end of the guide member and within the ET, wherein the bend of the guide member guides the expandable element into the ET as the dilation catheter is advanced relative to the guide member; and (e) expanding the expandable element of the dilation catheter uniformly in a radial direction to thereby dilate the ET, wherein the circumference of the expandable element is in contact with the circumference of the ET.
19. The method of claim 18, wherein advancing the dilation catheter relative to the guide member further comprises advancing the dilation catheter such that a predetermined length of the dilation catheter extends distally out of the guide catheter.
20. The method of claim 18, further comprising advancing a guidewire relative to the guide member such that a distal portion of the guidewire is positioned distal to a distal end of the guide member and within the ET, wherein the bend of the guide member guides the guidewire into the ET as the guidewire is advanced relative to the guide member, wherein the act of advancing the dilation catheter relative to the guide member comprises advancing the dilation catheter along the advanced guidewire.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) While the specification concludes with claims which particularly point out and distinctly claim this technology, it is believed this technology will be better understood from the following description of certain examples taken in conjunction with the accompanying drawings, in which like reference numerals identify the same elements and in which:
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
DETAILED DESCRIPTION
(24) The following detailed description should be read with reference to the drawings, in which like elements in different drawings are identically numbered. The drawings, which are not necessarily to scale, depict exemplary examples for the purpose of explanation only and are not intended to limit the scope of the invention. The detailed description illustrates by way of example, not by way of limitation, the principles of the invention. This description will clearly enable one skilled in the art to make and use the invention, and describes several examples, adaptations, variations, alternative and uses of the invention, including what is presently believed to be the best mode of carrying out the invention.
(25) As used herein, the terms about and approximately for any numerical values or ranges indicate a suitable dimensional tolerance that allows the part or collection of components to function for its intended purpose as described herein.
(26) I. Exemplary Eustachian Tube Dilation Catheter System
(27) One example of a treatment that may be performed to treat an ET (26) that does not provide sufficient communication between the middle ear (14) and the pharyngeal ostium (28) includes accessing and dilating the ET (26) using a guide catheter (100) and a balloon dilation catheter (200), examples of which are shown in
(28)
(29) The distal portion (120) of guide catheter (100) is shown in an enlarged view in
(30) Referring again to
(31) Balloon dilation catheter (200) of the present example is shown in
(32) Balloon (204) may be expanded to dilate the ET (26) after balloon (204) is placed in a desirable location in the ET (26), as shown in
(33) Balloon dilation catheter (200) further includes an actuator (210). Actuator (210) has a proximal side 220 and a distal side (222). In the example shown in
(34) The distal end (218) of balloon catheter (200) further includes a tip (212) and a flexible shaft portion (250) that is constructed of a polymeric material including but not limited to PEBAX (polyether block amide) that extends from the distal end of the elongate shaft (202) to the proximal end of balloon (204). In the example shown in
(35) After balloon (204) is positioned within the ET (26) and inflated to an expanded state (e.g., as shown in
(36) Another exemplary guide catheter (300) is shown in
(37) II. Exemplary Endoscope
(38) Referring to
(39) As noted above, an endoscope (60) may be used to provide visualization within an anatomical passageway (e.g., within the nasal cavity, etc.) during a process of using dilation catheter system, which in one example includes the balloon dilation catheter (200, 300) and, optionally, guide catheter (100). As shown in
(40) Body (62) of the present example includes a light post (70), an eyepiece (72), a rotation dial (74), and a pivot dial (76). Light post (70) is in communication with the light transmitting fibers in shaft (64) and is configured to couple with a source of light, to thereby illuminate the site in the patient distal to window (66). Eyepiece (72) is configured to provide visualization of the view captured through window (66) via the optics of endoscope (60). It should be understood that a visualization system (e.g., camera and display screen, etc.) may be coupled with eyepiece (72) to provide visualization of the view captured through window (66) via the optics of endoscope (60). Rotation dial (74) is configured to rotate shaft (64) relative to body (62) about the longitudinal axis of shaft (64). It should be understood that such rotation may be carried out even while the swing prism is pivoted such that the line of sight is non-parallel with the longitudinal axis of shaft (64). Pivot dial (76) is coupled with the swing prism and is thereby operable to pivot the swing prism about the transverse pivot axis. Indicia (78) on body (62) provide visual feedback indicating the viewing angle. Various suitable components and arrangements that may be used to couple rotation dial (74) with the swing prism will be apparent to those of ordinary skill in the art in view of the teachings herein. By way of example only, endoscope (60) may be configured in accordance with at least some of the teachings of U.S. Pub. No. 2010/0030031, now abandoned, the disclosure of which is incorporated by reference herein. In some versions, endoscope (60) is configured similar to the Acclarent Cyclops Multi-Angle Endoscope by Acclarent, Inc. of Menlo Park, Calif. Other suitable forms that endoscope (60) may take will be apparent to those of ordinary skill in the art in view of the teachings herein
(41) III. Exemplary Method of Treating the Eustachian Tube
(42)
(43) As shown in
(44) In an alternative example, a balloon catheter (200) is advanced into a nostril of a patient without the use of a guide catheter (100). The balloon (204) of the balloon catheter (200) is placed within the ET (26). The physician/user will advance the balloon catheter (200) until the proximal side (220) of the actuator (210) is adjacent the patient's nostril. The distal side (222) of the actuator (210) will bottom out against the patient's nostril, such that the balloon catheter cannot advance any further. The actuator (210) prevents the catheter from passing the isthmus (29) and reaching the middle ear (14). Further, actuator (210) can be positioned at the appropriate distance along the elongate shaft (202) such that access to the ET (26) may be from the contralateral or the ipsilateral side.
(45) Any number of procedures may be carried out following placement of the balloon catheter (200) into the desired position as described above. For instance, the Eustachian tube (ET) may be dilated by communicating fluid to balloon (204) and thereby inflating balloon (204), in accordance with the teachings of various reference cited herein or otherwise. In addition or in the alternative, the isthmus (29) may be cleaned and/or otherwise treated as described in U.S. Patent Application No. 62/139,919, entitled Method and Apparatus for Cleaning Isthmus of Eustachian Tube, filed Mar. 30, 2015, the disclosure of which is incorporated by reference herein.
(46) The elongate shaft (202) contains adjacent dual lumen (232, 234) tubing (see
(47) It may be desirable to inject solutions containing contrast agents, pharmaceutically acceptable salt or dosage form of an antimicrobial agent (e.g. antibiotic, antiviral, anti-parasitic, antifungal, etc.), an anesthetic agent with or without a vasoconstriction agent (e.g. Xylocaine with or without epinephrine, Tetracaine with or without epinephrine, etc.), an analgesic agent, a corticosteroid or other anti-inflammatory (e.g. an NSAID), a decongestant (e.g. vasoconstrictor), a mucus thinning agent (e.g. an expectorant or mucolytic), a surfactant, an agent that prevents or modifies an allergic response (e.g. an antihistamine, cytokine inhibitor, leucotriene inhibitor, IgE inhibitor, immunomodulator), an allergen or another substance that causes secretion of mucous by tissues, hemostatic agents to stop bleeding, antiproliferative agents, cytotoxic agents (e.g. alcohol), biological agents such as protein molecules, stem cells, genes or gene therapy preparations, or the like.
(48) Some nonlimiting examples of antimicrobial agents that may be used in this invention include acyclovir, amantadine, aminoglycosides (e.g., amikacin, gentamicin and tobramycin), amoxicillin, amoxicillinlclavulanate, amphotericin B, ampicillin, ampicillinlsulbactam, atovaquone, azithromycin, cefazolin, cefepime, cefotaxime, cefotetan, cefpodoxime, ceflazidime, ceflizoxime, ceftriaxone, cefuroxime, cefuroxime axetil, cephalexin, chloramphenicol, clotrimazole, ciprofloxacin, clarithromycin, clindamycin, dapsone, dicloxacillin, doxycycline, erythromycin, fluconazole, foscamet, ganciclovir, atifloxacin, imipenemlcilastatin, isoniazid, itraconazole, ketoconazole, metronidazole, nafcillin, nafcillin, nystatin, penicillin, penicillin G, pentamidine, pip eracillinitazobactam, rifampin, quinupristindalfopristin, ticarcillinlclavulanate, trimethoprimlsulfamethoxazole, valacyclovir, vancomycin, mafenide, silver sulfadiazine, mupirocin (e.g., Bactroban, Glaxo SmithKline, Research Triangle Park, N.C.), nystatin, triamcinolonelnystatin, clotrimazolelbetamethasone, clotrimazole, ketoconazole, butoconazole, miconazole, tioconazole, detergent-like chemicals that disrupt or disable microbes (e.g., nonoxynol-9, octoxynol-9, benzalkonium chloride, menfegol, and N-docasanol); chemicals that block microbial attachment to target cells and/or inhibits entry of infectious pathogens (e.g., sulphated and sulphonated polymers such as PC-515 (carrageenan), Pro-2000, and Dextrin 2 Sulphate); antiretroviral agents (e.g., PMPA gel) that prevent retroviruses from replicating in the cells; genetically engineered or naturally occurring antibodies that combat pathogens such as anti-viral antibodies genetically engineered from plants known as plantibodies; agents which change the condition of the tissue to make it hostile to the pathogen (such as substances which alter mucosal pH (e.g., Buffer Gel and Acid form); non-pathogenic or friendly microbes that cause the production of hydrogen peroxide or other substances that kill or inhibit the growth of pathogenic microbes (e.g., lactobacillus); antimicrobial proteins or peptides such as those described in U.S. Pat. No. 6,716,813 (Lin et al.,) which is expressly incorporated herein by reference or antimicrobial metals (e.g., colloidal silver).
(49) Additionally or alternatively, in some applications where it is desired to treat or prevent inflammation the substances delivered in this invention may include various steroids or other anti-inflammatory agents (e.g., nonsteroidal anti-inflammatory agents or NSAIDS), analgesic agents or antipyretic agents. For example, corticosteroids that have previously administered by intranasal 10 administration may be used, such as beclomethasone (Vancenase or Beconase), flunisolide (Nasalid), fluticasone proprionate (Flonase), triamcinolone acetonide (Nasacort), budesonide (Rhinocort Aqua), loterednol etabonate (Locort) and mometasone (Nasonex). Other salt forms of the aforementioned corticosteroids may also be used. Also, other non-limiting examples of steroids that may be useable in the present invention include but are not limited to aclometasone, desonide, hydrocortisone, betamethasone, clocortolone, desoximetasone, fluocinolone, flurandrenolide, mometasone, prednicarbate; amcinonide, desoximetasone, diflorasone, fluocinolone, fluocinonide, halcinonide, clobetasol, augmented betamethasone, diflorasone, halobetasol, prednisone, dexarnethasone and methylprednisolone. Other anti-inflammatory, analgesic or antipyretic agents that may be used include the nonselective COX inhibitors (e.g., salicylic acid derivatives, aspirin, sodium salicylate, choline magnesium trisalicylate, salsalate, diflunisal, sulfasalazine and olsalazine; para-aminophenol derivatives such as acetaminophen; indole and indene acetic acids such as indomethacin and sulindac; heteroaryl acetic acids such as tolmetin, dicofenac and ketorolac; arylpropionic acids such as ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen and oxaprozin; anthranilic acids (fenamates) such as mefenamic acid and meloxicam; enolic acids such as the oxicams (piroxicam, meloxicam) and alkanones such as nabumetone) and Selective COX-2 Inhibitors (e.g., diaryl-substituted furanones such as rofecoxib; diaryl-substituted pyrazoles such as celecoxib; indole acetic acids such as etodolac and sulfonanilides such as mmesulide).
(50) Additionally or alternatively, in some applications, such as those where it is desired to treat or prevent an allergic or immune response and/or cellular proliferation, the substances delivered in this invention may include a) various cytokine inhibitors such as humanized anti-cytokine antibodies, anti-cytokine receptor antibodies, recombinant (new cell resulting from genetic recombination) antagonists, or soluble receptors; b) various leucotriene modifiers such as zafirlukast, montelukast and zileuton; c) immunoglobulin E (IgE) inhibitors such as Omalizumab (an anti-IgE monoclonal antibody formerly called rhu Mab-E25) and secretory leukocyte protease inhibitor) and d) SYK Kinase inhibitors such as an agent designated as R-112, manufactured by Rigel Pharmaceuticals, Inc, South San Francisco, Calif.
(51) Additionally or alternatively, in some applications, such as those where it is desired to shrink mucosal tissue, cause decongestion, or effect hemostasis, the substances delivered in this invention may include various vasoconstrictors for decongestant and or hemostatic purposes including but not limited to pseudoephedrine, xylometazoline, oxymetazoline, phenylephrine, epinephrine, etc.
(52) Additionally or alternatively, in some applications, such as those where it is desired to facilitate the flow of mucous, the substances delivered in this invention may include various mucolytics or other agents that modify the viscosity or consistency of mucous or mucoid secretions, including but not limited to acetylcysteine. In one particular example, the substance delivered by this invention comprises a combination of an anti-inflammatory agent (e.g. a steroid or an NSAID) and a mucolytic agent.
(53) Additionally or alternatively, in some applications such as those where it is desired to prevent or deter histamine release, the substances delivered in this invention may include various mast cell stabilizers or drugs which prevent the release of histamine such as cromolyn (e.g., Nasal Chroma) and nedocromil.
(54) Additionally or alternatively, in some applications such as those where it is desired to prevent or inhibit the effect of histamine, the substances delivered in this invention may include various antihistamines such as azelastine (e.g., Astylin) diphenhydramine, loratidine, etc.
(55) Additionally or alternatively, in some examples such as those where it is desired to dissolve, degrade, cut, break or remodel bone or cartilage, the substances delivered in this invention may include substances that weaken or modify bone and/or cartilage to facilitate other procedures of this invention wherein bone or cartilage is remodeled, reshaped, broken or removed. One example of such an agent would be a calcium chelator such as EDTA that could be injected or delivered in a substance delivery implant next to a region of bone that is to be remodeled or modified. Another example would be a preparation consisting of or containing bone degrading cells such as osteoclasts. Other examples would include various enzymes of material that may soften or break down components of bone or cartilage such as collagenase (CGN), trypsin, trypsinlLEDTA, hyaluronidase, and tosyllysylchloromethane (TLCM).
(56) Additionally or alternatively, in some applications such as those wherein it is desired to treat a tumor or cancerous lesion, the substances delivered in this invention may include antitumor agents (e.g., cancer chemotherapeutic agents, biological response modifiers, vascularization inhibitors, hormone receptor blockers, cryotherapeutic agents or other agents that destroy or inhibit neoplasia or tumorigenesis) such as; alkylating agents or other agents which directly kill cancer cells by attacking their DNA (e.g., cyclophosphamide, isophosphamide), nitrosoureas or other agents which kill cancer cells by inhibiting changes necessary for cellular DNA repair (e.g., carmustine (BCNU) and lomustine (CCNU)), antimetabolites and other agents that block cancer cell growth by interfering with certain cell functions, usually DNA synthesis (e.g., 6 mercaptopurine and 5-fluorouracil (5FU), antitumor antibiotics and other compounds that act by binding or intercalating DNA and preventing RNA synthesis (e.g., doxorubicin, daunorubicin, epirubicin, idarubicin, mitomycin-C and bleomycin) plant (vinca) alkaloids and other antitumor agents derived from plants (e.g., vincristine and vinblastine), steroid hormones, hormone inhibitors, hormone receptor antagonists and other agents which affect the growth of hormone-responsive cancers (e.g., tamoxifen, herceptin, aromatase inhibitors such as aminoglutethamide and formestane, trriazole inhibitors such as letrozole and anastrazole, steroidal inhibitors such as exemestane), antiangiogenic proteins, small molecules, gene therapies and/or other agents that inhibit angiogenesis or vascularization of tumors (e.g., meth-I, meth-2, thalidomide), bevacizumab (Avastin), squalamine, endostatin, angiostatin, Angiozyme, AE-941 (Neovastat), CC-5013 (Revimid), medi-522 (Vitaxin), 2-methoxyestradiol (2ME2, Panzem), carboxyamidotriazole (CAI), combretastatin A4 prodrug (CA4P), SU6668, SU11248, BMS-275291, COL-3, EMD 121974, 1MC-IC11, 1M862, TNP-470, celecoxib (Celebrex), rofecoxib (Vioxx), interferon alpha, interleukin-12 (IL-12) or any of the compounds identified in Science Vol. 289, Pages 1197-1201 (Aug. 17, 2000) which is expressly incorporated herein by reference, biological response modifiers (e.g., interferon, bacillus calmetteguerin (BCG), monoclonal antibodies, interluken 2, granulocyte colony stimulating factor (GCSF), etc.), PGDF receptor antagonists, herceptin, asparaginase, busulphan, carboplatin, cisplatin, carmustine, cchlorambucil, cytarabine, dacarbazine, etoposide, flucarbazine, fluorouracil, gemcitabine, hydroxyurea, ifosphamide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, thioguanine, thiotepa, tomudex, topotecan, treosulfan, vinblastine, vincristine, mitoazitrone, oxaliplatin, procarbazine, streptocin, taxol, taxotere, analogslcongeners and derivatives of such compounds as well as other antitumor agents not listed here.
(57) Additionally or alternatively, in some applications such as those where it is desired to grow new cells or to modify existing cells, the substances delivered in this invention may include cells (mucosal cells, fibroblasts, stem cells or genetically engineered cells) as well as genes and gene delivery vehicles like plasmids, adenoviral vectors or naked DNA, mRNA, etc. injected with genes that code for anti-inflammatory substances, etc., and, as mentioned above, osteoclasts that modify or soften bone when so desired, cells that participate in or effect mucogenesis or ciliagenesis, etc.
(58) In one example, a local anesthetic, such as Lidocaine is injected through the injection lumen (234) prior to dilation of the ET (26). The injection lumen (234) can be used for venting during dilation so that pressure in the middle ear (14) does not increase or decrease.
(59) IV. Exemplary Alternative Balloon Catheter
(60) In some instances, it may be difficult or impossible to access the ET (26) by inserting instruments through the nostril, into the oro-nasal cavity, and through the pharyngeal ostium, as shown in
(61)
(62) By way of example only, guide catheter (1100) may have a length between about 12 cm and about 19 cm, or more particularly between about 14 cm and about 17 cm, or more particularly about 15.5 cm. Alternatively, guide catheter (1100) may have a length of about 15.8 cm. By way of further example only, guide catheter (1100) may have a diameter between about 2.75 mm and about 3.75 mm, or more particularly between about 3 mm and about 3.5 mm, or more particularly about 3.3 mm. By way of further example only, guide catheter (1100) may have a bend angle between about 45 and about 65, or more particularly between about 50 and about 60, or more particularly about 55.
(63)
(64) The distal portion (1120) of guide catheter (1100) is shown in an enlarged view in
(65) Referring again to
(66)
(67) The balloon dilation catheter (1200) generally includes a proximally located connection (1230) for inflating/activating the balloon (1204) by communicating a pressurized medium (e.g., saline) to balloon (1204). Balloon (1204) may be expanded to dilate the ET (26) after balloon (1204) is placed in a desirable location in the ET (26), in a similar manner as shown in
(68) Balloon dilation catheter (1200) further includes an actuator (1210). Actuator (1210) has a proximal side (1220) and a distal side (1222). In the example shown in
(69) The distal end (1218) of balloon catheter (1200) further includes a tip (1212) and a flexible shaft portion (1250) that is constructed of a polymeric material including but not limited to PEBAX (polyether block amide) that extends from the distal end of the elongate shaft (1202) to the proximal end of balloon (1204). In the example shown in
(70) After balloon (1204) is positioned within the ET (26) and inflated to an expanded state (e.g., as shown in
(71) V. Exemplary Alternative Method of Treating the Eustachian Tube Via Oral Approach
(72)
(73) In some versions, guide catheter (1100) and balloon catheter (1200) are inserted together, as a unit, through the mouth (15) and into the oro-nasal cavity, with tip (1212) of balloon catheter (1200) being located at or proximal to distal tip (1124) of guide catheter (1100). In some other versions, guide catheter (1100) is first inserted through the mouth (15) and into the oro-nasal cavity; and then balloon catheter (1200) is inserted into guide catheter (1100) after guide catheter (1100) has been positioned in the mouth (15) and oro-nasal cavity. In either case, distal tip (1124) of guide catheter (1100) is eventually positioned at, in, or near the pharyngeal ostium (28), which opens into the ET (26). In the example shown in
(74) Once guide catheter (1100) has been suitably positioned in relation to the pharyngeal ostium (28), and particularly after guidewire (80) is positioned in the ET (26) via the pharyngeal ostium (28), balloon catheter (1200) is then advanced distally relative to guide catheter (1100) to position balloon (1204) in the ET (26). Once balloon (1204) is positioned in the ET (26), the operator may inflate the balloon (1204) to dilate the ET (26), as shown in
(75) VI. Exemplary Combinations
(76) The following examples relate to various non-exhaustive ways in which the teachings herein may be combined or applied. It should be understood that the following examples are not intended to restrict the coverage of any claims that may be presented at any time in this application or in subsequent filings of this application. No disclaimer is intended. The following examples are being provided for nothing more than merely illustrative purposes. It is contemplated that the various teachings herein may be arranged and applied in numerous other ways. It is also contemplated that some variations may omit certain features referred to in the below examples. Therefore, none of the aspects or features referred to below should be deemed critical unless otherwise explicitly indicated as such at a later date by the inventors or by a successor in interest to the inventors. If any claims are presented in this application or in subsequent filings related to this application that include additional features beyond those referred to below, those additional features shall not be presumed to have been added for any reason relating to patentability.
Example 1
(77) A method of dilating a first Eustachian tube (ET) of a patient using a dilation catheter, wherein the method comprises: (a) directing the dilation catheter into the mouth of the patient; (b) advancing the dilation catheter into a first ET on one side of the patient's head while a proximal portion of the dilation catheter is disposed in the mouth of the patient; and (c) expanding the expandable member to thereby dilate the first ET
Example 2
(78) The method of Example 1, further comprising: (a) repositioning the dilation catheter relative to a second ET on another side of the patient's head while a proximal portion of the dilation catheter is disposed in the mouth of the patient; (b) advancing the dilation catheter into the second ET while a proximal portion of the dilation catheter is disposed in the mouth of the patient; and (c) expanding the expandable member to thereby dilate the second ET.
Example 3
(79) The method of any one or more of Examples 1 through 2, further comprising: (a) directing a guide member into the mouth of the patient; and (b) advancing at least part of a distal portion of the guide member adjacent to an opening of a first ET on one side of the patient's head; wherein the act of advancing the dilation catheter comprises advancing the dilation catheter relative to the guide member, wherein the guide member directs the dilation catheter into the first ET during the act of advancing the dilation catheter relative to the guide member; wherein a proximal portion of the guide member is disposed in the mouth of the patient during the act of advancing the dilation catheter relative to the guide member.
Example 4
(80) The method of Example 3, wherein the distal portion of the guide member comprises a bend.
Example 5
(81) The method of Example 4, wherein the bend has a bend angle between about 45 and about 65.
Example 6
(82) The method of any one or more of Examples 3 through 5, wherein the guide catheter has a length between about 14 cm and about 17 cm.
Example 7
(83) The method of any one or more of Examples 3 through 7, further comprising: (a) repositioning the guide catheter relative to a second ET on another side of the patient's head while a proximal portion of the guide catheter is disposed in the mouth of the patient; and (b) advancing the dilation catheter relative to the repositioned guide catheter to thereby drive the dilation catheter into the second ET while a proximal portion of the dilation catheter is disposed in the mouth of the patient.
Example 8
(84) The method of any one or more of Examples 1 through 7, wherein the expandable member comprises an inflatable balloon, wherein the act of expanding the expandable member comprises inflating the balloon.
Example 9
(85) The method of any one or more of Examples 1 through 8, wherein the expandable member comprises a mechanically expandable element, wherein the act of expanding the expandable member comprises expanding the expandable element.
Example 10
(86) The method of any one or more of Examples 1 through 9, further comprising displacing a portion of a soft palate of the mouth.
Example 11
(87) The method of Example 10, wherein displacing the portion of the soft palate comprises tying down the soft palate.
Example 12
(88) The method of any one or more of Examples 1 through 11, further comprising delivering a therapeutic agent to the first ET.
Example 13
(89) A method of dilating Eustachian tubes (ETs) of a patient using a dilation catheter, wherein the method comprises: (a) directing the dilation catheter into an oro-nasal cavity of the patient via the patient's mouth; (b) advancing the dilation catheter into a first ET of the patient; (c) expanding an expandable member of the dilation catheter to thereby dilate the first ET; (d) repositioning the dilation catheter toward a second ET of the patient without removing the dilation catheter from the oro-nasal cavity; (e) advancing the dilation catheter into the second ET; and (f) expanding the expandable member of the dilation catheter to thereby dilate the second ET.
Example 14
(90) The method of Example 13, wherein the dilation catheter has a length of between about 20 cm and about 40 cm.
Example 15
(91) The method of any one or more of Examples 13 through 14, wherein the dilation catheter comprises a shaft, wherein the shaft has a diameter between about 0.7 mm and about 1.1 mm.
Example 16
(92) The method of any one or more of Examples 13 through 15, wherein steps (a) through (f) are all performed using a single hand.
Example 17
(93) The method of any one or more of Examples 13 through 16, further directing a guide catheter into the oro-nasal cavity of the patient via the patient's mouth, wherein the act of advancing the dilation catheter comprises advancing the dilation catheter through the guide catheter.
Example 18
(94) A method of dilating a Eustachian tube (ET) of a patient using a guide member and a dilation catheter, wherein the method comprises: (a) directing the guide member into a mouth of the patient; (b) directing the dilation catheter into the mouth of the patient via the guide member; (c) advancing at least part of a distal portion of the guide member adjacent to an opening of the ET while a proximal portion of the guide member remains disposed in the mouth of the patient, wherein the distal portion of the guide member has a bend; (d) advancing the dilation catheter relative to the guide member such that an expandable element of the dilation catheter is positioned distal to a distal end of the guide member and within the ET, wherein the bend of the guide member guides the expandable element into the ET as the dilation catheter is advanced relative to the guide member; and (e) expanding an expandable member of the dilation catheter to thereby dilate the ET.
Example 19
(95) The method of Example 18, wherein advancing the dilation catheter relative to the guide member further comprises advancing the dilation catheter such that a predetermined length of the dilation catheter extends distally out of the guide catheter.
Example 20
(96) The method of any one or more of Examples 18 through 19, further comprising advancing a guidewire relative to the guide member such that a distal portion of the guidewire is positioned distal to a distal end of the guide member and within the ET, wherein the bend of the guide member guides the guidewire into the ET as the guidewire is advanced relative to the guide member, wherein the act of advancing the dilation catheter relative to the guide member comprises advancing the dilation catheter along the advanced guidewire.
(97) VII. Miscellaneous
(98) It should be understood that any of the examples described herein may include various other features in addition to or in lieu of those described above. By way of example only, any of the examples described herein may also include one or more of the various features disclosed in any of the various references that are incorporated by reference herein.
(99) It should be understood that any one or more of the teachings, expressions, examples, examples, etc. described herein may be combined with any one or more of the other teachings, expressions, examples, examples, etc. that are described herein. The above-described teachings, expressions, examples, examples, etc. should therefore not be viewed in isolation relative to each other. Various suitable ways in which the teachings herein may be combined will be readily apparent to those of ordinary skill in the art in view of the teachings herein. Such modifications and variations are intended to be included within the scope of the claims.
(100) It should be appreciated that any patent, publication, or other disclosure material, in whole or in part, that is said to be incorporated by reference herein is incorporated herein only to the extent that the incorporated material does not conflict with existing definitions, statements, or other disclosure material set forth in this disclosure. As such, and to the extent necessary, the disclosure as explicitly set forth herein supersedes any conflicting material incorporated herein by reference. Any material, or portion thereof, that is said to be incorporated by reference herein, but which conflicts with existing definitions, statements, or other disclosure material set forth herein will only be incorporated to the extent that no conflict arises between that incorporated material and the existing disclosure material.
(101) Versions described above may be designed to be disposed of after a single use, or they can be designed to be used multiple times. Versions may, in either or both cases, be reconditioned for reuse after at least one use. Reconditioning may include any combination of the steps of disassembly of the device, followed by cleaning or replacement of particular pieces, and subsequent reassembly. In particular, some versions of the device may be disassembled, and any number of the particular pieces or parts of the device may be selectively replaced or removed in any combination. Upon cleaning and/or replacement of particular parts, some versions of the device may be reassembled for subsequent use either at a reconditioning facility, or by a user immediately prior to a procedure. Those skilled in the art will appreciate that reconditioning of a device may utilize a variety of techniques for disassembly, cleaning/replacement, and reassembly. Use of such techniques, and the resulting reconditioned device, are all within the scope of the present application.
(102) By way of example only, versions described herein may be sterilized before and/or after a procedure. In one sterilization technique, the device is placed in a closed and sealed container, such as a plastic or TYVEK bag. The container and device may then be placed in a field of radiation that can penetrate the container, such as gamma radiation, x-rays, or high-energy electrons. The radiation may kill bacteria on the device and in the container. The sterilized device may then be stored in the sterile container for later use. A device may also be sterilized using any other technique known in the art, including but not limited to beta or gamma radiation, ethylene oxide, or steam.
(103) Having shown and described various examples of the present invention, further adaptations of the methods and systems described herein may be accomplished by appropriate modifications by one of ordinary skill in the art without departing from the scope of the present invention. Several of such potential modifications have been mentioned, and others will be apparent to those skilled in the art. For instance, the examples, examples, geometries, materials, dimensions, ratios, steps, and the like discussed above are illustrative and are not required. Accordingly, the scope of the present invention should be considered in terms of the following claims and is understood not to be limited to the details of structure and operation shown and described in the specification and drawings.